Article

October 29, 2014

UnitedHealth Continues Its Acquisition Spree

Optum, UHC's technology and services subsidiary, has bought Allere's wellness subsidiaries.

UnitedHealth continued its shopping spree on Tuesday with Optum, the group's technology and services subsidiary, agreeing to pay $600 million to acquire Alere Inc.'s condition management and wellness subsidiaries

Specializing in infectious and cardiometabolic disease diagnostics, the Waltham, Massachusetts-based Alere's wellness offerings serve about 200 regional health plans, 89 Fortune 500 employers and 22 million people nationally. The company, however, is trying to reduce costs and sell "non-core assets" — such as the chronic condition management, smoking cessation and home-based obstetrical services Optum is buying — in an effort to "sharpen its strategic focus" on the global rapid diagnostics market.

Read the complete article on Healthcare Payer News: http://bit.ly/1FVKtpK

Related Videos

Related Content

May 12th 2021

US Cost-effectiveness and Budget Impact of Point-of-Care NAAT for Streptococcus

S. Pinar Bilir, MS Eliza Kruger, MHEcon Mathilde Faller, MA Julie Munakata, MS James K. Karichu, PhD, MPH Joanna Sickler, MPH, MBA Mindy M. Cheng, PhD, MS

This study evaluates the cost-effectiveness and budget impact to US payers of point-of-care nucleic acid amplification tests (NAAT) for group A streptococcus.

April 11th 2020

Putting the Patient Back at the Center of Patient-Centered Care

Joseph Alvarnas, MD

From the editor-in-chief of Evidence-Based Oncology™.

March 3rd 2020

Personalized Medicine: The Role of Technology and Diagnostics in Driving Change

Laura Joszt, MA Mary Caffrey

Rebecca Kaul, MBA, vice president and chief innovation officer at The University of Texas MD Anderson Cancer Center, said the best technology improves the patient experience.

Study Finds Imaging Technique Could Replace Riskier Diagnostic Method for Diabetic Retinopathy

August 30th 2019

Study Finds Imaging Technique Could Replace Riskier Diagnostic Method for Diabetic Retinopathy

Diabetic retinopathy costs the United States $6.2 billion a year. Better screening techniques that can catch neurodegeneration at earlier stages have the potential to cut costs and improve quality of life for patients.

August 26th 2019

Cancer & Blood Specialists of Louisville Adds New PET/CT Scanner to Improve Cancer Treatment

Patients to benefit from new technology that enables physicians to more accurately diagnose and locate cancers.

Biomarker Could Warn of CV Event Risk in Absence of Being Overweight

August 24th 2019

Biomarker Could Warn of CV Event Risk in Absence of Being Overweight

Adding measurement of a key protein during metabolic assessment could help identify those at higher risk of heart attacks and strokes even if they have normal body mass index.

Related Content

May 12th 2021

US Cost-effectiveness and Budget Impact of Point-of-Care NAAT for Streptococcus

S. Pinar Bilir, MS Eliza Kruger, MHEcon Mathilde Faller, MA Julie Munakata, MS James K. Karichu, PhD, MPH Joanna Sickler, MPH, MBA Mindy M. Cheng, PhD, MS

This study evaluates the cost-effectiveness and budget impact to US payers of point-of-care nucleic acid amplification tests (NAAT) for group A streptococcus.

April 11th 2020

Putting the Patient Back at the Center of Patient-Centered Care

Joseph Alvarnas, MD

From the editor-in-chief of Evidence-Based Oncology™.

March 3rd 2020

Personalized Medicine: The Role of Technology and Diagnostics in Driving Change

Laura Joszt, MA Mary Caffrey

Rebecca Kaul, MBA, vice president and chief innovation officer at The University of Texas MD Anderson Cancer Center, said the best technology improves the patient experience.

Study Finds Imaging Technique Could Replace Riskier Diagnostic Method for Diabetic Retinopathy

August 30th 2019

Study Finds Imaging Technique Could Replace Riskier Diagnostic Method for Diabetic Retinopathy

Diabetic retinopathy costs the United States $6.2 billion a year. Better screening techniques that can catch neurodegeneration at earlier stages have the potential to cut costs and improve quality of life for patients.

August 26th 2019

Cancer & Blood Specialists of Louisville Adds New PET/CT Scanner to Improve Cancer Treatment

Patients to benefit from new technology that enables physicians to more accurately diagnose and locate cancers.

Biomarker Could Warn of CV Event Risk in Absence of Being Overweight

August 24th 2019

Biomarker Could Warn of CV Event Risk in Absence of Being Overweight

Adding measurement of a key protein during metabolic assessment could help identify those at higher risk of heart attacks and strokes even if they have normal body mass index.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions